FMP

FMP

Enter

Barclays Sets a Price Target for Teva Pharmaceutical Industries Ltd. 

-

twitterlinkedinfacebook
blog post cover photo

Image credit: Google Images

  • Barclays has set a new price target for Teva Pharmaceutical at $21, indicating a potential upside of about 26.28%.
  • Teva's recovery is attributed to the success of newer drugs like Austedo, Uzedy, and Ajovy, along with a stable generics business.
  • The company's stock has seen a significant increase of 135% over the past year, with a current market capitalization of approximately $18.64 billion.

Balaji Prasad from Barclays recently set a new price target for NYSE:TEVA, Teva Pharmaceutical Industries Ltd., at $21, which is a significant jump from its current trading price of $16.63. This new target suggests a potential upside of about 26.28%, indicating a bullish outlook on the stock. Teva, a global pharmaceutical company, is known for its wide range of generic and specialty medicines. The company has been in the spotlight for its remarkable recovery, with its stock price increasing by 135% over the past year.

This optimistic price target by Barclays is supported by Teva's impressive performance and strategic focus on its newer drugs, such as Austedo, Uzedy, and Ajovy. These drugs have played a crucial role in the company's recovery, contributing to its soaring stock price. Additionally, Teva's stable generics business is expected to further boost its top-line growth in the coming quarters. This combination of successful new drug launches and a robust generics business forms the backbone of the positive outlook on Teva's stock.

Teva's stock has experienced significant volatility, with its price fluctuating between a low of $7.22 and a high of $17.39 over the past year. Despite the recent decrease of 2.06% in its stock price, the company maintains a strong market capitalization of approximately $18.64 billion. The trading volume of 7,338,079 shares indicates active interest in Teva's stock among investors.

The company's listing on the New York Stock Exchange (NYSE) and its substantial market presence underscore its importance in the pharmaceutical industry. Competing against both generic and specialty pharmaceutical companies, Teva's strategic initiatives and focus on growth-driving drugs have positioned it well for future success.

In conclusion, the new price target set by Barclays reflects confidence in Teva's strategic direction and its ability to sustain the impressive growth witnessed over the past year. With a solid pipeline of drugs and a stable generics business, Teva is well-equipped to continue its upward trajectory, making it a stock to watch in the pharmaceutical sector.

Other Blogs

Sep 10, 2024 11:33 AM - Parth Sanghvi

Best Alternatives to Yahoo Finance for Downloading Historical Stock Data

When it comes to downloading historical stock data, Yahoo Finance has been a popular choice for many. However, for those looking for more comprehensive, accurate, and flexible options, Financial Modeling Prep (FMP) offers a suite of powerful tools and services that stand out as superior alternatives...

blog post title

Nov 8, 2024 10:30 AM - Sanzhi Kobzhan

Understanding Equity Valuation: When to Use DCF, DDM, and Price-Income (Multiplicators) Models

When it comes to investing in stocks, one of the key decisions an investor must make involves determining the intrinsic value of a company's shares. Equity valuation isn't just about numbers, it's an art mixed with science, aiming to predict future performance based on current and historical data. H...

blog post title

Nov 22, 2024 10:08 AM - Parth Sanghvi

Fundamental Analysis: Principles, Types, and How to Use It

Fundamental analysis is one of the most essential tools for investors and analysts alike, helping them assess the intrinsic value of a stock, company, or even an entire market. It focuses on the financial health and economic position of a company, often using key data such as earnings, expenses, ass...

blog post title
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep